Compounding Pharmacies Behind GLP-1 Telehealth: 503A vs 503B, How to Verify a License, and What the Label Must Say

Why the pharmacy matters more than the telehealth brand

The telehealth company you sign up with does not make your medication. It employs or contracts clinicians who prescribe, and it routes the prescription to a pharmacy that compounds and ships it. The pharmacy is where quality, sterility, potency and labeling are determined. Two providers with identical prices can use pharmacies with very different quality systems, and a provider can change pharmacies without telling you. Every provider page on this site records the pharmacy type and, where verified, the pharmacy name; where a provider has not disclosed it, the field says so.

503A pharmacies

A 503A pharmacy is a traditional compounding pharmacy licensed by its state board. It compounds a drug for an identified individual patient on receipt of a valid prescription. In exchange for that patient-specific model, section 503A of the Federal Food, Drug, and Cosmetic Act exempts it from three requirements that apply to manufacturers: current good manufacturing practice (CGMP), FDA premarket approval, and labeling with adequate directions for use. Quality is governed by state law and by United States Pharmacopeia chapters (USP <797> for sterile preparations, <795> for non-sterile). A 503A pharmacy shipping across state lines needs a nonresident license in the destination state, and several states limit or require additional registration for sterile compounded products, which is why some providers exclude certain states.

503B outsourcing facilities

A 503B outsourcing facility, created by the Drug Quality and Security Act of 2013 after the 2012 meningitis outbreak, registers with the FDA, follows CGMP, is inspected by the FDA on a risk-based schedule, and reports adverse events to the FDA. It may compound without patient-specific prescriptions for office use, and it may compound in larger batches. Because batches are not patient-specific, the post-shortage rule against compounding "essentially a copy" of an approved drug bites harder on 503B facilities; many 503B facilities stopped producing compounded GLP-1s after the FDA's 2025 deadlines, and several telehealth providers moved to 503A pharmacies as a result.

What neither designation means

Neither 503A nor 503B compounding produces an FDA-approved drug. The FDA does not review the safety, effectiveness or quality of any compounded product before it is sold. A 503B facility's CGMP compliance is a manufacturing-quality claim, not an approval claim. Providers that describe their compounded medication as "FDA-approved" or "from an FDA-approved pharmacy" are wrong; the accurate statements are "prepared by a state-licensed 503A pharmacy" or "prepared by an FDA-registered 503B outsourcing facility."

The legal basis for compounding after the shortage

Since December 19, 2024 (tirzepatide) and February 21, 2025 (semaglutide), the FDA no longer lists these drugs as in shortage. Compounding a copy of Zepbound, Mounjaro, Wegovy or Ozempic is therefore not permitted. Compounding for an individual patient remains permitted when the prescriber determines that the patient needs a formulation that differs from the approved product — a different strength, an additive such as vitamin B12, a different dosage form — and documents that determination. The FDA has said it will not treat a formulation change made merely to avoid the copy prohibition as a legitimate clinical need. A patient cannot resolve this question by reading a website; what a patient can do is confirm that the pharmacy is licensed, that the label lists the base peptide and its concentration, and that the prescriber has documented the reason for compounding.

Verifying a pharmacy in five minutes

1. Ask the provider for the dispensing pharmacy's name, city and state, and whether it is 503A or 503B.
2. Look up the pharmacy on your state board of pharmacy's license search (start at the NABP directory). Confirm an active nonresident license if the pharmacy is out of state.
3. For a 503B facility, confirm it appears on the FDA's registered outsourcing facilities list and check for warning letters or Form 483 observations.
4. Check the FDA's compounding warning letters page for the pharmacy's name.
5. When the medication arrives, read the label for the drug name and salt form, the mg/mL concentration, the beyond-use date and storage instructions. Photograph it and keep it with your dosing instructions.

Formulations

Compounded GLP-1 vials commonly contain the peptide with a preservative (benzyl alcohol or phenol), a buffer, and sometimes an additive: vitamin B12 as cyanocobalamin or methylcobalamin, or L-carnitine. The additives are marketed for energy or nausea, are not supported by trials for either purpose in this context, and are one of the ways pharmacies produce a formulation that differs from the approved product. Our B12 vs L-carnitine guide explains what is and is not known.

The pharmacies we track

Provider pages list the pharmacy type and name as verified. NexLife has not published its dispensing pharmacy on the plan pages we verified; the field is marked pending and we have asked. See the service areas page for state coverage.